When does GMP actually start?

Good Manufacturing Practice (GMP) is often treated as a regulatory threshold that begins once a product enters formal manufacturing. In reality, this interpretation is incomplete and can lead to significant compliance gaps. GMP is not a single event or phase gate; it is a continuum of control that progressively increases as products move from early development through to commercial production.

The question of when GMP actually starts is therefore not simply regulatory but structural. It depends on how materials are intended to be used, the level of control required to ensure data integrity, and the stage at which decisions begin to impact patient safety, clinical outcomes, or commercial supply.

Understanding the true starting point of GMP is essential for building appropriate quality systems, avoiding retrospective compliance fixes, and ensuring that data generated throughout development remains suitable for regulatory submission.

GMP as a Risk-Based Continuum

GMP is fundamentally risk-based. It applies whenever the risk associated with product quality, patient safety, or data integrity justifies formal control. This means that GMP principles can be relevant long before a product is commercially manufactured.

In early research environments, activities are often exploratory and flexible. However, even at this stage, certain GMP-aligned principles begin to emerge. These include controlled documentation of experimental work, traceability of materials, calibration of critical equipment, and consistent recording of results.

As development progresses, the degree of control increases. Processes become defined, materials are standardised, and procedures are formalised. At this point, GMP is no longer theoretical; it begins to shape how work is performed and recorded.

The transition is gradual rather than abrupt, driven by increasing regulatory expectations and the growing importance of the data being generated.

Early Development and the Emergence of Control

In discovery and early preclinical research, full GMP compliance is generally not required. However, this does not mean that quality control is absent. Scientific integrity still depends on reproducibility, traceability, and accurate recording of experimental conditions.

At this stage, good documentation practices form the foundation of future GMP systems. Laboratory notebooks, instrument logs, and electronic records must be sufficiently detailed to allow reconstruction of experiments. Material identity and source tracking become important when results may later support regulatory submissions.

Although formal GMP structures are not fully implemented, the principles of control begin to take shape. These early controls are often described as “GMP-like” because they anticipate the requirements that will later become mandatory.

Preclinical Development and Increasing Regulatory Expectation

GMP expectations become more defined when development transitions into regulated preclinical studies. Materials intended for toxicology studies, pharmacokinetic analysis, or safety assessment may need to be manufactured under controlled conditions consistent with GMP principles.

At this stage, consistency of material becomes critical. Variability in test articles can directly affect study outcomes and regulatory interpretation. As a result, production of investigational materials often requires documented procedures, controlled environments, and qualified equipment.

Good Laboratory Practice frameworks often intersect with GMP principles during this phase. While GLP governs the conduct of studies, GMP principles ensure that the materials used in those studies are suitable, consistent, and traceable.

This overlap represents one of the first clear indicators that GMP has effectively begun, even if not yet applied in its full commercial form.

Clinical Trial Material and Formal GMP Application

The clearest point at which GMP formally applies is during the manufacture of investigational medicinal products intended for human use. Once materials are administered to clinical trial participants, regulatory expectations become significantly more stringent.

Clinical trial material must be produced under controlled conditions that ensure identity, strength, quality, and purity. Manufacturing processes must be documented, reviewed, and approved. Facilities must operate under defined environmental controls, and personnel must be trained and qualified for their roles.

Batch records become essential evidence of compliance. These records document every step of production, including raw material use, process parameters, in-process testing, and final release decisions.

At this stage, GMP is no longer optional or interpretive. It is a defined regulatory requirement governing all aspects of production and release for clinical use.

Commercial Manufacturing and Full GMP Implementation

Full GMP implementation occurs when a product enters commercial manufacturing. At this point, the objective shifts from producing clinical material for limited use to consistently supplying marketed products to patients.

Commercial GMP requires validated processes, robust quality management systems, and continuous oversight of manufacturing and testing activities. Process validation demonstrates that production systems operate consistently within defined parameters. Analytical validation ensures that testing methods provide reliable and reproducible results.

Change control systems become essential to manage modifications to processes, equipment, or materials. Deviations must be investigated to determine root cause and product impact. Product release decisions are based on comprehensive review of all manufacturing and quality data.

Inspection readiness becomes a continuous requirement. Regulatory authorities expect that organisations can demonstrate control of their processes at any time.

The Misconception of a Single GMP Start Point

A common misconception is that GMP begins at a clearly defined moment, such as the initiation of clinical trials or the start of commercial manufacturing. This interpretation oversimplifies the regulatory framework and can lead to gaps in quality control during early development.

In reality, GMP exists as a progressive system of increasing control. Certain principles apply from the earliest stages of development, while full regulatory requirements become mandatory only at defined transition points.

Treating GMP as a binary concept creates risk because it encourages organisations to delay implementation of critical controls until too late in the development lifecycle.

Transition Points Where GMP Becomes Explicit

Although GMP is continuous in principle, there are specific transition points where its application becomes formally mandatory.

The first occurs when materials are manufactured for use in humans. At this point, clinical GMP requirements apply fully. The second occurs when products move into commercial supply, triggering full regulatory oversight for marketed goods.

Between these points, GMP requirements increase in complexity and stringency. Systems evolve from flexible research controls to validated, fully documented manufacturing systems.

Managing these transitions effectively requires structured planning, risk assessment, and progressive system development.

Building GMP Readiness Early

Organisations that prepare for GMP early in development reduce regulatory risk and improve operational efficiency. Early implementation of controlled documentation, defined procedures, and structured training systems ensures that later transition into formal GMP environments is smoother and less disruptive.

Equipment qualification, analytical method development, and process characterisation conducted early in development provide a foundation for later validation activities. Similarly, establishing change control and deviation management systems before they are strictly required improves organisational maturity.

GMP readiness is therefore not achieved at a single milestone but built progressively through disciplined development practices.

Conclusion

GMP does not begin at a single identifiable moment. It begins as soon as controlled processes and regulated decision-making become necessary to ensure product quality and patient safety. While full GMP requirements are formally applied during clinical manufacturing and commercial production, its principles extend throughout the entire product lifecycle.

Understanding GMP as a continuum rather than a fixed starting point enables organisations to design appropriate quality systems from the outset. This approach reduces risk, improves data integrity, and ensures that when regulatory scrutiny increases, systems are already capable of meeting expectations without disruption.

GMP effectively starts when control becomes essential, and it evolves continuously as products move from concept to patient use.